Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 29 Oct 2026
Standard addition

Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA)

First gene therapy for a rare genetic brain disorder showed potential to slow cognitive decline, though patients need careful monitoring for liver complications.

This regulatory evidence review of an open-label study with external natural-history controls examined Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA). The first approved disease-modifying therapy for MPS IIIA improved modeled cognitive outcomes and lowered cerebrospinal-fluid heparan sulfate, with substantial liver-enzyme elevations and serious adverse events requiring follow-up.

What the study was

Study design
Regulatory evidence review of an open-label study with external natural-history controls
Population
Young children with mucopolysaccharidosis type IIIA and preserved neurodevelopmental function
Sample size
17 early-treated patients and 27 external controls
Category
Treatment Innovation
Maturity
Potentially Practice-Changing
Journal
Drug discoveries & therapeutics

Why it surfaced

Regulatory evidence review of an open-label study with external natural-history controls; The first approved disease-modifying therapy for MPS IIIA improved modeled cognitive outcomes and lowered cerebrospinal-fluid heparan sulfate, with substantial liver-enzyme elevations and serious adverse events requiring follow-up. Score kept conservative because only the PubMed abstract and metadata were reviewed.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.